BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 27
• 28
• 29
• 30
• 31

• 

  Collaboration

  Lilly Makes $780M+ IPF Play with Mediar Partnership

  Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early studies have found to be safe and capable of engaging its target.

  January 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  ALS

  HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail

  Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the latest setbacks for the controversial platform trial, the results from which have largely mirrored the dismal success rate in ALS overall.

  January 10, 2025

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Drug pricing

  Part D Drugs Almost Doubled in Cost Since Launch, Underscoring Importance of IRA: AARP

  Concurrently, a preprint from the industry-backed Vital Transformation found a 50% drop in company investments into small-molecule drug development.

  January 10, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Venture capitalists

  Lilly Partners With a16z on $500M VC Fund for Early-Stage Biotechs

  The Biotech Ecosystem Venture Fund will combine the sourcing capabilities of venture capital firm Andreessen Horowitz (a16z) with Eli Lilly’s expertise in R&D—plus half a billion in capital from the Big Pharma.

  January 10, 2025

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Series A

  MyoKardia Alumni Launch Kardigan with $300M to Tackle Heart Disease

  After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are back together with a mission to make cardiovascular disease curable and preventable.

  January 10, 2025

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Cardiovascular disease

  Marea Posts Positive Phase II Data for Remnant Cholesterol Lowering mAb

  Research has shown remnant cholesterol is a significant factor in cardiovascular disease risk.

  January 10, 2025

   · 

  1 min read

   · 

  Kate Goodwin
• 

  Bladder cancer

  Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda

  If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor indicated in combination with BCG for high-risk non-muscle invasive bladder cancer patients who had not previously undergone BCG treatment.

  January 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  A Conversation with Peter Marks and Tom Whitehead: Insights into GenScript Biotech Forum 2025 (Teaser)

  In this short teaser, BioSpace’s Head of Insights Lori Ellis talks to CBER Director Peter Marks and Tom Whitehead, Co-Founder of the Emily Whitehead Foundation about anticipated discussions at the upcoming GenScript Biotech Forum.

  January 10, 2025

   · 

  1 min read

   · 

  Lori Ellis
• 

  Layoffs

  IGM Biosciences Lays Off 73% of Staff, Shrinks Pipeline

  Staff cuts will leave IGM Biosciences with 37 employees. The company is also halting development of two bispecific antibody T cell engagers for autoimmune diseases.

  January 10, 2025

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Startups

  GSK-backed Ouro Launches With $120M to ‘Reset’ the Immune System

  Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated diseases.

  January 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac